However, seasoned pharmaceutical investors recognize the industry's cyclical nature. The industry's rhythm of drug development, regulatory hurdles, marketing pushes, and patent expirations means that ...

Dividend investing hardly loses its allure but gains more attention when the Fed cuts interest rates. A recent report from ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Nvidia is expected to boost the S&P 500 Q3 earnings growth rate. Meta Platforms and Alphabet may lift Communications Services earnings.